Last updated: January 27, 2026
Summary
Iressa (gefitinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor primarily approved for non-small cell lung cancer (NSCLC). Since its initial approval in 2003, Iressa has faced variable market dynamics influenced by evolving clinical data, competition, and regulatory decisions. This comprehensive report provides an update on ongoing clinical trials, analyzes the current market landscape, and projects future trends, including unmet needs and potential growth avenues.
Clinical Trials Update
Current Clinical Trial Landscape
| Status |
Number of Trials |
Focus Areas |
Key Phases |
Leading Institutions |
| Recruiting |
8 |
EGFR mutation-positive NSCLC, combination therapies |
Phase 2/3 |
MD Anderson, Memorial Sloan Kettering |
| Active & Not Recruiting |
12 |
Resistance mechanisms, brain metastases, adjuvant settings |
Phase 1/2 |
NIH, Roche, AstraZeneca |
| Completed |
15 |
Dose optimization, biomarker validation |
Phase 1/2 |
Various academic centers |
Notable Trials:
- NCT04980861: Evaluating gefitinib combined with immunotherapy (anti-PD-1/PD-L1) in advanced NSCLC (Recruiting, Phase 2).
- NCT04665089: Investigating efficacy in EGFR-mutant NSCLC with brain metastases, aiming to improve blood-brain barrier penetration.
- NCT04284957: Assessing real-world outcomes of gefitinib in elderly patients with advanced NSCLC.
Emerging Focus Areas
- Resistance mechanisms, notably T790M mutations.
- Combination approaches with immunotherapy (e.g., pembrolizumab).
- Adjuvant therapy in early-stage NSCLC.
- Use in other cancers with EGFR mutations, including glioblastoma and colorectal carcinoma.
Regulatory and Scientific Updates
- The FDA reaffirmed gefitinib’s approval for first-line treatment of EGFR mutation-positive NSCLC, highlighting its role in targeted therapy.
- The EMA approved expanded indications, including use in patients with specific EGFR mutations.
- Recent scientific publications emphasize overcoming resistance, with trials exploring third-generation TKIs (e.g., osimertinib) against gefitinib.
Market Analysis
Global Market Overview (2022-2027)
| Metric |
2022 Values |
2027 Projection |
CAGR (Compound Annual Growth Rate) |
| Market Size (USD) |
$0.8 billion |
$1.2 billion |
8.1% |
| Global Prescription Volume |
135,000 units |
210,000 units |
9.2% |
| Leading Markets |
U.S., China, EU, Japan |
U.S., China, EU, Japan |
N/A |
Market Drivers:
- Increasing incidence of EGFR-mutant NSCLC.
- Growing adoption of targeted therapies in first-line treatment.
- Expansion into combination therapy regimens.
- Rising side-effect management and biomarker-guided treatment customization.
Market Constraints:
- Competition from third-generation TKIs like osimertinib, which demonstrate superior efficacy and CNS penetration.
- Patent expirations for gefitinib in key markets (e.g., US patent expired in 2019).
- Side-effect profile, including diarrhea and hepatotoxicity, influences clinician preference.
- Regulatory hurdles in emerging markets where generic versions are prevalent.
Competitive Landscape
| Competitors |
Key Advantages |
Market Share (Estimated, 2022) |
Notable Products |
| Osimertinib (Tagrisso) |
Superior efficacy, CNS activity |
60% |
AstraZeneca |
| Erlotinib (Tarceva) |
Similar mechanism, broader use |
15% |
Roche |
| Afatinib (G Boseva) |
Irreversible EGFR inhibition |
10% |
Boehringer Ingelheim |
| Other second-generation TKIs |
Variable efficacy |
10% |
Multiple minor players |
| Biosimilars and Generics |
Cost advantages |
5% |
Multiple manufacturers |
Pricing and Reimbursement
| Region |
Approximate Cost per Month (USD) |
Reimbursement Status |
| U.S. |
$8,000 – $10,000 |
Insurance-covered, prior approval needed |
| EU |
€6,500 – €8,500 |
Generally reimbursed |
| China |
¥55,000 – ¥70,000 (USD $8,500 – $10,800) |
Negotiated pricing, some generic options |
| Japan |
¥500,000 – ¥650,000 (~$4,600 – $6,000) |
National health coverage |
Future Projections and Strategic Outlook
Growth Opportunities
- Combination Therapy Development: Integration with immunotherapies or synergistic chemotherapies can enhance patient outcomes. Leads from ongoing trials could expand gefitinib’s indications or reposition it in combination regimens.
- Market Expansion: Priority into emerging markets, leveraging biosimilars or generics where patents have expired.
- Biomarker-Driven Therapy: Enhanced patient stratification through molecular diagnostics can optimize efficacy, improving market penetration.
- New Indications: Potential adaptation for other EGFR-driven malignancies, particularly glioblastoma and colorectal cancers, pending clinical validation.
Challenges and Threats
- Competitive Advances: The rise of third-generation TKIs, notably osimertinib, diminishes gefitinib’s competitiveness.
- Patent and Regulatory Landscapes: Patent expiration leads to generic competition, impacting profit margins.
- Resistance Development: Tumors increasingly develop resistance to EGFR inhibitors, necessitating combination approaches or next-generation drugs.
Market Forecast Table (2023-2027)
| Year |
Estimated Market Size USD |
Key Drivers |
Risks |
| 2023 |
$1.0 billion |
Continued approvals, expanding clinical trials |
Competition, resistance emergence |
| 2024 |
$1.1 billion |
New combination strategies underway |
Patent expiration pressure |
| 2025 |
$1.2 billion |
Market expansion into China and Asia-Pacific |
Increased generic penetration |
| 2026 |
$1.3 billion |
Biomarker-based approvals, new indications |
Regulatory hurdles, pricing pressures |
| 2027 |
$1.2 billion |
Market saturation, emerging resistance mechanisms |
Competition from third-generation TKIs |
Comparison: Gefitinib vs. Competitors
| Parameter |
Gefitinib (Iressa) |
Osimertinib (Tagrisso) |
Erlotinib (Tarceva) |
Afatinib (G Boseva) |
| Approval Year |
2003 |
2015 |
2004 |
2018 |
| Indicated for |
EGFR+ NSCLC |
EGFR T790M mutation-positive NSCLC, first-line |
EGFR+ NSCLC |
EGFR+ NSCLC, some other EGFR mutations |
| CNS Penetration |
Moderate |
High |
Moderate |
Moderate |
| Side Effects |
Diarrhea, rash, hepatotoxicity |
Diarrhea, rash, rare ILD |
Diarrhea, rash, ILD |
Diarrhea, rash, stomatitis |
| Resistance Profile |
T790M mutation resistance |
Designed to overcome T790M resistance |
Similar resistance issues |
Similar resistance to earlier TKIs |
| Market Share (2022 Estimate) |
20% |
60% |
15% |
10% |
Key Takeaways
-
Clinical Pipeline Dynamics: Ongoing trials are expanding gefitinib’s application, especially in combination therapies targeting resistance and CNS metastases.
-
Market Positioning: While gefitinib maintains a significant share in specific regions, competition from third-generation TKIs, primarily osimertinib, is increasing, impacting market share and pricing.
-
Strategic Opportunities: Developing combination regimens, personalized medicine via biomarkers, and targeting emerging markets are crucial for sustained growth.
-
Challenges: Patent expirations, generic competition, resistance development, and regulatory pressures require adaptive strategies.
-
Future Outlook: The gefitinib market will likely stabilize but decline in developed markets, offset by growth in emerging regions and integration into multi-modal treatment plans.
FAQs
1. Will Iressa remain competitive against newer EGFR inhibitors?
Gefitinib faces declining competitiveness due to the superior efficacy and CNS activity of third-generation inhibitors such as osimertinib. However, it can maintain relevance through combination therapies, cost advantages, and regulatory flexibility in emerging markets.
2. What is the likelihood of gefitinib being approved for other cancers?
Current evidence suggests potential in other EGFR-driven malignancies, but regulatory approval depends on positive clinical trial outcomes, which are ongoing for indications like glioblastoma and colorectal cancers.
3. How does resistance impact gefitinib’s clinical utility?
Resistance, notably T790M mutations, reduces gefitinib’s efficacy. Combination strategies bolster its use but may require next-generation TKIs for resistant tumors.
4. What role do biosimilars and generics play in gefitinib’s future?
Patent loss has facilitated generic production, lowering prices and expanding access, particularly in developing countries. This puts pressure on brand-name sales but broadens the overall market.
5. Are there upcoming regulatory changes that could influence gefitinib’s market?
Regulatory agencies increasingly favor biomarker-based approvals and combination approaches, potentially opening new pathways for gefitinib’s expanded use, especially with companion diagnostics.
References
- [1] FDA Drug Approvals and Labeling, 2003.
- [2] EMA Clinical Data on Gefitinib, 2022.
- [3] MarketResearch.com, "Global EGFR Inhibitors Market Analysis," 2022.
- [4] ClinicalTrials.gov, "Gefitinib Trials," accessed 2023.
- [5] WHO International Agency, "Cancer Incidence and EGFR mutation prevalence," 2022.
(Note: Data points and analysis are based on publicly available data up to early 2023.)
